Takeda makes US R&D appointment
This article was originally published in Scrip
Executive Summary
Dr Azmi Nabulsi has been appointed president of the Takeda Global Research & Development Center in the US. He succeeds Dr Nancy Joseph-Ridge, who has been named general manager of the Japanese firm's US pharmaceutical development division. This operates under Takeda Pharmaceuticals International, a new wholly owned US entity formed in a recent restructuring of corporate R&D activities (scripnews.com, March 31st, 2009). Dr Nabulsi joined Takeda in 2004 and was most recently general manager of the strategic development department at its Osaka headquarters.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.